125 related articles for article (PubMed ID: 2674337)
41. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
42. Serum beta 2 microglobulin and its prognostic value in lymphomas.
Amlot PL; Adinolfi M
Eur J Cancer (1965); 1979 May; 15(5):791-6. PubMed ID: 92408
[No Abstract] [Full Text] [Related]
43. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
44. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
45. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma.
Avilés A; Díaz-Maqueo JC; Rodriguez L; García EL; Guzmán R; Talavera A
Hematol Oncol; 1991; 9(2):115-21. PubMed ID: 1869242
[TBL] [Abstract][Full Text] [Related]
47. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.
Suzuki K; Terui Y; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Tsuyama N; Takeuchi K; Hatake K
Jpn J Clin Oncol; 2013 Jan; 43(1):37-44. PubMed ID: 23166385
[TBL] [Abstract][Full Text] [Related]
49. Plasma TM2-PK levels in mycosis fungoides patients.
Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
[TBL] [Abstract][Full Text] [Related]
50. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.
Hagberg H; Siegbahn A
Scand J Haematol; 1983 Jul; 31(1):49-56. PubMed ID: 6867608
[TBL] [Abstract][Full Text] [Related]
52. Treatment of lymphoblastic lymphoma in adults.
Coleman CN; Picozzi VJ; Cox RS; McWhirter K; Weiss LM; Cohen JR; Yu KP; Rosenberg SA
J Clin Oncol; 1986 Nov; 4(11):1628-37. PubMed ID: 3772416
[TBL] [Abstract][Full Text] [Related]
53. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
Duan Y; Li G; Hu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
[TBL] [Abstract][Full Text] [Related]
55. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma.
Endrizzi L; Fiorentino MV; Salvagno L; Segati R; Pappagallo GL; Fosser V
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):945-9. PubMed ID: 6891644
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
57. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
58. Serum beta 2 microglobulin in malignant lymphoproliferative disorders.
Constantinides IP; Pathouli C; Karvountzis G; Papadopoulos P; Varvoutsi-Constantinides M; Eliakis P; Hadziyannis S; Komninos Z
Cancer; 1985 May; 55(10):2384-9. PubMed ID: 3886124
[TBL] [Abstract][Full Text] [Related]
59. Clinical and biological significance of serum tumor markers in adult T-cell leukemia.
Sadamori N
Leuk Lymphoma; 1996 Aug; 22(5-6):415-9. PubMed ID: 8882954
[TBL] [Abstract][Full Text] [Related]
60. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
